BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/10/2021 9:08:48 AM | Browse: 1017 | Download: 2177
 |
Received |
|
2021-03-16 16:47 |
|
Peer-Review Started |
|
2021-03-16 16:54 |
|
First Decision by Editorial Office Director |
|
2021-05-01 04:55 |
|
Return for Revision |
|
2021-05-01 04:55 |
|
Revised |
|
2021-05-12 15:20 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-11-25 05:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-11-28 07:18 |
|
Articles in Press |
|
2021-11-28 07:18 |
|
Edit the Manuscript by Language Editor |
|
2021-11-24 03:35 |
|
Typeset the Manuscript |
|
2021-12-07 02:46 |
|
Publish the Manuscript Online |
|
2021-12-10 09:08 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Saeideh Momtaz and Amir Hossein Abdolghaffari |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Amir Hossein Abdolghaffari, PhD, Assistant Professor, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran 1941933111, Iran. amirhosein172@hotmail.com |
| Key Words |
Inflammatory bowel diseases; COVID-19; Transmembrane serine protease 2; Inflammation; Pro-inflammatory; Immunological responses |
| Core Tip |
This article provides clinical evidence on synthetic or natural-based transmembrane serine protease 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE2) inhibitors, which are able to reduce coronavirus disease 2019-induced inflammation and cytokine storms in inflammatory bowel disease patients. Hence, targeting TMPRSS2 and ACE2 could be noticed as a novel approach for inflammatory bowel diseases treatment. |
| Publish Date |
2021-12-10 09:08 |
| Citation |
Lashgari NA, Roudsari NM, Momtaz S, Abdolghaffari AH. Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment. World J Gastroenterol 2021; 27(46): 7943-7955
|
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i46/7943.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i46.7943 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
